MA43178A - Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci - Google Patents
Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ciInfo
- Publication number
- MA43178A MA43178A MA043178A MA43178A MA43178A MA 43178 A MA43178 A MA 43178A MA 043178 A MA043178 A MA 043178A MA 43178 A MA43178 A MA 43178A MA 43178 A MA43178 A MA 43178A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- synthesis
- treatment
- drug conjugates
- epothilone analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562242702P | 2015-10-16 | 2015-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43178A true MA43178A (fr) | 2018-09-12 |
Family
ID=58518025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043178A MA43178A (fr) | 2015-10-16 | 2016-10-14 | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci |
Country Status (10)
Country | Link |
---|---|
US (1) | US10874646B2 (fr) |
EP (1) | EP3371176A4 (fr) |
JP (1) | JP2018534283A (fr) |
CN (1) | CN108430996A (fr) |
AU (1) | AU2016340093A1 (fr) |
BR (1) | BR112018007673A2 (fr) |
CA (1) | CA3002027A1 (fr) |
MA (1) | MA43178A (fr) |
MX (1) | MX2018004696A (fr) |
WO (1) | WO2017066606A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4043451B1 (fr) * | 2019-10-18 | 2024-02-28 | FMC Corporation | Procédés de préparation d'un intermédiaire dans la synthèse de l'acide 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylique |
CN114650984A (zh) * | 2019-10-18 | 2022-06-21 | Fmc公司 | 用于制备5-溴-2-(3-氯-吡啶-2-基)-2h-吡唑-3-甲酸的方法 |
KR20220084131A (ko) * | 2019-10-18 | 2022-06-21 | 에프엠씨 코포레이션 | 5-브로모-2-(3-클로로-피리딘-2-일)-2h-피라졸-3-카복실산의 제조 방법 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
CA2360952A1 (fr) * | 1999-02-11 | 2000-08-17 | Schering Aktiengesellschaft | Derives d'epothilone, leur procede de production et leur utilisation pharmaceutique |
US7125893B1 (en) * | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
EP1959952A4 (fr) | 2005-11-22 | 2011-02-23 | Scripps Research Inst | Synthese chimique d'un epothilone tres puissant |
AR061181A1 (es) * | 2006-05-25 | 2008-08-13 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
EP1930004A1 (fr) | 2006-12-08 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Utilisation d'épothylones dans le traitement de l'ostéoporose et des maladies associées |
EP2009114A1 (fr) * | 2007-06-29 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Procédés, kits et composés pour déterminer la réactivité au traitement d'un trouble pathologique par épothilones |
CN101519404B (zh) * | 2008-02-29 | 2016-01-20 | 唐莉 | 15环噻酮衍生物及其制备方法与应用 |
US20150314007A1 (en) * | 2012-12-21 | 2015-11-05 | Glykos Finland Oy | Linker-payload molecule conjugates |
US20140323533A1 (en) * | 2013-04-29 | 2014-10-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
-
2016
- 2016-10-14 MX MX2018004696A patent/MX2018004696A/es unknown
- 2016-10-14 EP EP16856299.9A patent/EP3371176A4/fr not_active Withdrawn
- 2016-10-14 CN CN201680074140.0A patent/CN108430996A/zh active Pending
- 2016-10-14 CA CA3002027A patent/CA3002027A1/fr active Pending
- 2016-10-14 AU AU2016340093A patent/AU2016340093A1/en not_active Abandoned
- 2016-10-14 MA MA043178A patent/MA43178A/fr unknown
- 2016-10-14 US US15/768,800 patent/US10874646B2/en active Active
- 2016-10-14 BR BR112018007673A patent/BR112018007673A2/pt not_active Application Discontinuation
- 2016-10-14 WO PCT/US2016/057093 patent/WO2017066606A1/fr active Application Filing
- 2016-10-14 JP JP2018519372A patent/JP2018534283A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018004696A (es) | 2018-11-29 |
CA3002027A1 (fr) | 2017-04-20 |
US20190022069A1 (en) | 2019-01-24 |
WO2017066606A1 (fr) | 2017-04-20 |
EP3371176A1 (fr) | 2018-09-12 |
JP2018534283A (ja) | 2018-11-22 |
BR112018007673A2 (pt) | 2018-11-06 |
AU2016340093A1 (en) | 2018-05-10 |
CN108430996A (zh) | 2018-08-21 |
US10874646B2 (en) | 2020-12-29 |
EP3371176A4 (fr) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
IL274938A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
MA45192A (fr) | Traitement d'association | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
MA49715A (fr) | Oligomères et conjugués d'oligomères | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
FI20145492A (fi) | Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen | |
MA48709A (fr) | Conjugués de médicament à base de silicium et leurs procédés d'utilisation | |
MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
MA44987A (fr) | Formulations de médicaments améliorées | |
FR3056393B1 (fr) | Orthese d'extension de machoires | |
BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
MA51295A (fr) | Dosage, procédé et traitement d'alpha-synucléinopathies | |
DK3275457T3 (da) | Farmaceutisk sammensætning omfattende silybin og pu'er-te-essens | |
MA42264A (fr) | Procédé de préparation d'oltipraz | |
MA49555A (fr) | Procédé amélioré de préparation d'imetelstat | |
MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
BR112018005305A2 (pt) | agente profilático ou terapêutico da queratite fungal | |
MA42130A (fr) | Combinaisons d'opioïdes et de n-acyléthanolamines |